FR2969493B1 - Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant du bpo - Google Patents

Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant du bpo

Info

Publication number
FR2969493B1
FR2969493B1 FR1061168A FR1061168A FR2969493B1 FR 2969493 B1 FR2969493 B1 FR 2969493B1 FR 1061168 A FR1061168 A FR 1061168A FR 1061168 A FR1061168 A FR 1061168A FR 2969493 B1 FR2969493 B1 FR 2969493B1
Authority
FR
France
Prior art keywords
dermatological
gel
suspension containing
foams obtained
containing bpo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1061168A
Other languages
English (en)
Other versions
FR2969493A1 (fr
Inventor
Emmanuelle At
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Galderma Research and Development SNC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Research and Development SNC filed Critical Galderma Research and Development SNC
Priority to FR1061168A priority Critical patent/FR2969493B1/fr
Priority to CA2822547A priority patent/CA2822547A1/fr
Priority to US13/997,154 priority patent/US20130338235A1/en
Priority to PCT/FR2011/053161 priority patent/WO2012085483A1/fr
Priority to EP11815529.0A priority patent/EP2654718A1/fr
Publication of FR2969493A1 publication Critical patent/FR2969493A1/fr
Application granted granted Critical
Publication of FR2969493B1 publication Critical patent/FR2969493B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/38—Percompounds, e.g. peracids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions intermédiaires et en particulier des gels et suspensions pour la préparation de compositions mousse comprenant du péroxyde de benzoyle; ainsi que leur utilisation dermatologique.
FR1061168A 2010-12-23 2010-12-23 Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant du bpo Active FR2969493B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR1061168A FR2969493B1 (fr) 2010-12-23 2010-12-23 Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant du bpo
CA2822547A CA2822547A1 (fr) 2010-12-23 2011-12-22 Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant du peroxyde de benzoyle
US13/997,154 US20130338235A1 (en) 2010-12-23 2011-12-22 Dermatological foams obtained from a gel or suspension containing benzoyl peroxide
PCT/FR2011/053161 WO2012085483A1 (fr) 2010-12-23 2011-12-22 Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant du peroxyde de benzoyle
EP11815529.0A EP2654718A1 (fr) 2010-12-23 2011-12-22 Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant du peroxyde de benzoyle

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1061168A FR2969493B1 (fr) 2010-12-23 2010-12-23 Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant du bpo

Publications (2)

Publication Number Publication Date
FR2969493A1 FR2969493A1 (fr) 2012-06-29
FR2969493B1 true FR2969493B1 (fr) 2013-07-05

Family

ID=44202827

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1061168A Active FR2969493B1 (fr) 2010-12-23 2010-12-23 Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant du bpo

Country Status (5)

Country Link
US (1) US20130338235A1 (fr)
EP (1) EP2654718A1 (fr)
CA (1) CA2822547A1 (fr)
FR (1) FR2969493B1 (fr)
WO (1) WO2012085483A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104918598B (zh) * 2012-11-13 2018-12-04 盖尔德玛公司 Bpo清洗凝胶组合物
CN106456544B (zh) * 2014-03-28 2021-02-02 盖尔德马研究及发展公司 包含阿达帕林和过氧化苯甲酰的免洗型化学泡沫
BR112016022293A2 (pt) * 2014-03-28 2017-08-15 Galderma Res & Dev Composição que contém peróxido de benzoíla, uso cosmético de uma composição, medicamento destinado a uma aplicação tópica sobre a pele, kit e processo de preparação de uma composição autoespumante
BR112016022340A2 (pt) * 2014-03-28 2017-08-15 Galderma Res & Dev Composição, uso cosmético de uma composição, medicamento e kit
FR3041537B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee.
FR3041536B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'acne.
FR3041541B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee comprenant de l'ivermectine
FR3041538B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis.
FR3041539B1 (fr) 2015-09-29 2018-10-26 Galderma Research & Development Composition nettoyante auto-moussante contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis.
FR3041535B1 (fr) 2015-09-29 2019-01-25 Galderma Research & Development Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'ichtyose.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204093A (en) * 1989-04-06 1993-04-20 Victor Steven A Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and using same
MA22677A1 (fr) * 1991-10-16 1993-07-01 Richardson Vicks Inc Compositions cosmetiques en gels
NZ541526A (en) * 2003-01-24 2008-03-28 Stiefel Res Australia Pty Ltd Clindamycin phosphate foam
KR101368107B1 (ko) * 2006-03-31 2014-03-14 스티펠 리서치 오스트레일리아 피티와이 리미티드 발포성 현탁겔
WO2009069006A2 (fr) * 2007-11-30 2009-06-04 Foamix Ltd. Peroxyde de benzoyle contenant de la mousse
EP2395994A4 (fr) * 2009-02-12 2013-05-22 Prec Dermatology Inc Compositions moussantes de peroxyde de benzoyle pour administration topique
US20130108557A1 (en) * 2009-09-30 2013-05-02 Albert Zorko Abram Cosmetic foam
US9137596B2 (en) * 2012-10-30 2015-09-15 Harman International Industries, Inc. Splitter for earphones and headphones

Also Published As

Publication number Publication date
EP2654718A1 (fr) 2013-10-30
CA2822547A1 (fr) 2012-06-28
US20130338235A1 (en) 2013-12-19
FR2969493A1 (fr) 2012-06-29
WO2012085483A1 (fr) 2012-06-28

Similar Documents

Publication Publication Date Title
FR2969493B1 (fr) Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant du bpo
FR2969491B1 (fr) Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant une combinaison d'adapalene et de bpo
FR2969492B1 (fr) Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant de l'adapalene
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
MA34169B1 (fr) Dérivés d'acide 1-amino-2-cyclopropyléthylboronique
MA34780B1 (fr) Anticorps se liant de façon préférentielle au domaine extracellulaire 4 de csf1r human et leur utilisation
PH12015502575B1 (en) Piperidin-4-yl azetidine derivatives as jak1 inhibitors
MA31167B1 (fr) Inhibiteurs de l'activite de akt
MA32481B1 (fr) Compositions et procédés d'utilisation pour des anticorps thérapeutiques
BR112012032028A2 (pt) compostos de tioacetato, composições e métodos de uso.
MX2013004726A (es) Anticuerpos dkk1 y metodos de uso.
MA34019B1 (fr) Aryltriazolone liée à un bis-aryle et son utilisation
NO20073601L (no) Immunresponsmodifikator-skumformuleringer
MA35803B1 (fr) Polypeptides d'interleukine-2 mutants
MX2022009942A (es) Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
MX2008001614A (es) 7-aza-indazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
WO2011123727A3 (fr) Organosilicones
MA33492B1 (fr) Inhibiteurs de bace
EP4234698A3 (fr) Compositions et procédés d'utilisation d'anticorps thérapeutiques dirigés contre la protéine 6 liée à la lipoprotéine de basse densité (lrp6)
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
EP2371347A3 (fr) Compositions de soins buccaux
WO2008085221A3 (fr) Utilisation thérapeutique de cellules exprimant cd31
MA44593A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14